insights_auto
Why is GBT up 5.74%?
Dive Deeperchevron_right
GBT:EPA
Guerbet SA
€6.45
arrow_upward
+5.74%(+0.35) 1D
Nov 6, 5:35:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GBT...
Open
€6.12
High
€6.54
Low
€6.06
Mkt. cap
75.19M
Avg. vol.
12.75K
Volume
25.46K
52-wk high
€18.26
52-wk low
€5.80
EPS
-€11.05
Shares outstanding
12.64M
No. of employees
3K
Open
€6.12
High
€6.54
Low
€6.06
Mkt. cap
75.19M
Avg. vol.
12.75K
Volume
25.46K
52-wk high
€18.26
52-wk low
€5.80
EPS
-€11.05
Shares outstanding
12.64M
No. of employees
3K
News stories
From web sources and news partners
www.tmgm.com
·
4 hours ago
United States CFTC S&P 500 NC Net Positions up to $-129.4K from previous $-134.4K
marketscreener.com
·
4 hours ago
S&P 500 Posts Weekly Drop as Energy, Technology Slide in Election Aftermath
TradingView
·
4 hours ago
Nasdaq rebounds after tech selloff but sheds 3% for the week
Profile
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in over 20 countries including France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters is located in Villepinte, Seine-Saint-Denis.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product is produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories. Wikipedia
About Guerbet SA